Aptevo Therapeutics Past Earnings Performance

Past criteria checks 0/6

Aptevo Therapeutics has been growing earnings at an average annual rate of 36.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 31.3% per year.

Key information

36.1%

Earnings growth rate

58.1%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	-31.3%
Return on equity	-152.6%
Net Margin	n/a
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

Revenue & Expenses Breakdown
Beta

How Aptevo Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:APVO Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	0	-19	12
30 Sep 23	0	-18	12
30 Jun 23	0	-19	13
31 Mar 23	0	17	14
31 Dec 22	3	7	14
30 Sep 22	7	6	14
30 Jun 22	10	6	14
31 Mar 22	13	-30	15
31 Dec 21	12	-29	15
30 Sep 21	11	-30	16
30 Jun 21	9	-30	16
31 Mar 21	7	-29	14
31 Dec 20	4	-31	14
30 Sep 20	2	-33	13
30 Jun 20	0	-37	14
31 Mar 20	0	-41	15
31 Dec 19	0	-43	16
30 Sep 19	6	-48	19
30 Jun 19	12	-49	22
31 Mar 19	19	-52	25
31 Dec 18	23	-54	28
30 Sep 18	20	-49	30
30 Jun 18	20	-34	31
31 Mar 18	17	-35	32
31 Dec 17	15	-33	35
30 Sep 17	15	-39	34
30 Jun 17	11	-115	38
31 Mar 17	4	-119	37
31 Dec 16	10	-120	36
30 Sep 16	15	-122	42
30 Jun 16	19	-61	39
31 Mar 16	30	-61	43
31 Dec 15	34	-59	43
31 Dec 14	46	-51	34
31 Dec 13	0	-53	15

Quality Earnings: APVO is currently unprofitable.

Growing Profit Margin: APVO is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: APVO is unprofitable, but has reduced losses over the past 5 years at a rate of 36.1% per year.

Accelerating Growth: Unable to compare APVO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APVO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).

Return on Equity

High ROE: APVO has a negative Return on Equity (-152.61%), as it is currently unprofitable.

Aptevo Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2022 earnings: EPS exceeds analyst expectations

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Recent updates

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Price target increased by 49% to US$671

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

New major risk - Share price stability

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Price target decreased by 33% to US$12.00

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings: EPS exceeds analyst expectations

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to US$18.00

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Consensus revenue estimates fall by 15%

Price target decreased to US$52.50

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Price target decreased to US$59.50

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo gets $50/share takeout offer from shareholder Tang

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta